image header

News Releases

News Releases

Nov 11, 2021

ALX Oncology Reports Third Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights Read more

Nov 9, 2021

ALX Oncology Announces Updated Data from Ongoing Clinical Trial (ASPEN-01) of Evorpacept Showing Emerging Clinical Benefit in Survival-Based Endpoints in Patients with Advanced Solid Tumors Read more

Nov 4, 2021

ALX Oncology to Present New Evorpacept Clinical Data in Myelodysplastic Syndromes at 63rd ASH Annual Meeting Read more

Nov 2, 2021

ALX Oncology Announces Upcoming Virtual Investor Conference Participation Read more

Oct 21, 2021

ALX Oncology Announces First Patient Dosed in ASPEN-05, a Phase 1/2 Study of Evorpacept in Combination with Venetoclax and Azacitidine in Patients with Acute Myeloid Leukemia Read more

Oct 7, 2021

ALX Oncology Strengthens Immuno-Oncology Pipeline with Acquisition of ScalmiBio Read more

Oct 5, 2021

Zymeworks and ALX Oncology Announce First Patient Dosed in Phase 1b/2 Clinical Trial of Zanidatamab and Evorpacept (ALX148) in Patients with Advanced HER2-Expressing Breast Cancer and Other Solid Tumors Read more

Oct 1, 2021

ALX Oncology Announces Four Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting Read more

Sep 16, 2021

ALX Oncology Announces Initiation of Investigator-Sponsored Trial of Evorpacept (ALX148) in Patients with Indolent and Aggressive Non-Hodgkin Lymphoma Read more

Sep 7, 2021

ALX Oncology Announces Upcoming Virtual Investor Conference Participation Read more

Displaying 1 - 10 of 26